Clinical Trials Directory

Trials / Unknown

UnknownNCT03357978

Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia

Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia With and Without Substitution of Immunoglobulin G: a Prospective Observational Study

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Johann Wolfgang Goethe University Hospital · Academic / Other
Sex
All
Age
2 Years – 45 Years
Healthy volunteers
Not accepted

Summary

Ataxia telangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. The immunodeficiency is expressed by recurring infections. It's characterised by decreased lymphocytes data as well as lack of immunglobulin A, immunglobulin G subclasses and specific antibodies against pneumococcus. Aim of the present clinical trial is to investigate frequency-, intensity- and duration of the infections as well as changes oft immune status, dimension of liver disease and tumor risk in patients with A-T, with and without immunoglobulin G substitution therapy. Transient elastography (FibroScan) will be performed in order to measure liver stiffness as an indication of fatty liver and liver fibrosis. A bioelectrical impedance analysis (BIA) is conducted to investigate the exact body composition. Ataxia Score is determined to define neurological problems. Every subject receives a diary to compile symptoms of infection.

Detailed description

Ataxia teleangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. The immunodeficiency is expressed by recurring infections. It's characterised by decreased lymphocytes data as well as lack of immunglobulin A, immunglobulin G subclasses and specific antibodies against pneumococcus as shown in many trials. Additionally the patients suffer from a fatty liver with increased transaminases and have the risk for a cirrhosis of the liver and a hepatocellular carcinoma. It's known that the dimension of the liver disease affects susceptibility to infection. Nevertheless there are only a few studies treating this problem. Despite the proof of the immunodeficiency polyvalent immunoglobulins (IgG) are not given regularly. Own observations show that in spite of the treatment with immunoglobulins the progression of a chronic destructive lung disease with development of bronchiectasis hardly can prohibited. Up to now it isn't cleared if a substitution therapy with immunoglobulins reduces the susceptibility to infection. Therefore the aim oft the present clinical trial ist to explore frequency-, intensity, and duration oft the infections as well as changes oft the immune status, measure of liver disease and tumor risk in patients with A-T, with and without immunoglobulin therapy. The study includes five visits, which are performed in all A-T patients. Visit 1, 3, 5 are realized in the context of annual follow ups: * To evaluate weight and length of all subjects * To analyze the exact structure of single body compartments such as the lean mass, the water compartment or the fat compartment using bioelectrical impedance analysis * To define the neurological status by ataxia score * To get a detailed immune status, vaccination status and liver values as well as special tumor markers in blood * To check the lung function using spirometry * To measure liver stiffness using transient elastography (FibroScan) * To compile any symptoms of infection by diary * To investigate the ataxia status and physical condition by means of the Five-Times-Sit-to-Stand Test Visit 2 and 4 are additionally conducted as study visits: * To get a detailed immune status in blood * To check the lung function using spirometry

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTbioelectrical impedance analysisElectrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
DIAGNOSTIC_TESTblood drawBlood samples are taken from sober patients
DIAGNOSTIC_TESTtransient elastography (FibroScan)FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound
DIAGNOSTIC_TESTataxia scoreKlockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb
DIAGNOSTIC_TESTFive-Times-Sit-to-Stand TestThe test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series

Timeline

Start date
2016-10-01
Primary completion
2018-09-30
Completion
2019-09-30
First posted
2017-11-30
Last updated
2017-11-30

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT03357978. Inclusion in this directory is not an endorsement.